TY  - JOUR
AU  - Julià, Antonio
AU  - López-Lasanta, María
AU  - Blanco, Francisco
AU  - Gómez, Antonio
AU  - Haro, Isabel
AU  - Mas, Antonio Juan
AU  - Erra, Alba
AU  - Vivar, Ma Luz García
AU  - Monfort, Jordi
AU  - Sánchez-Fernández, Simón
AU  - González, Isidoro
AU  - Alperi, Mercedes
AU  - Castellanos-Moreira, Raúl
AU  - Fernández-Nebro, Antonio
AU  - Díaz-Torné, César
AU  - Palau, Núria
AU  - Lastra, Raquel
AU  - Lladós, Jordi
AU  - Sanmartí, Raimon
AU  - Marsal, Sara
PY  - 2021
DO  - 10.1186/s12891-021-04248-y
UR  - http://hdl.handle.net/10668/17615
T2  - BMC musculoskeletal disorders
AB  - Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50-60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and...
LA  - en
KW  - Anti-TNF therapy
KW  - Autoantibodies
KW  - Rheumatoid arthritis
KW  - Treatment response
KW  - Arthritis, Rheumatoid
KW  - Autoantibodies
KW  - Humans
KW  - Peptides, Cyclic
KW  - Prospective Studies
KW  - Retrospective Studies
KW  - Rheumatoid Factor
KW  - Tumor Necrosis Factor Inhibitors
TI  - Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy.
TY  - research article
VL  - 22
ER  -